51ST ANNUAL MEETING - Society for Surgery of the Alimentary Tract

THE SOCIETY FOR SURGERY OF THE ALIMENTARY TRACT
51ST ANNUAL MEETING • MAY 1–5, 2010 • NEW ORLEANS, LA
Sp483
Sp484
Sp485
Sp486
Endoscopic Diagnosis, Surveillance, and Management
of Small GISTs
William Brugge, Boston, MA
GIST Histopathology and Mutation Analysis
Christopher Corless, Portland, OR
Medical Management of Advanced GIST and Role of
Serum Drug-Level Testing
Margaret von Mehren, Philadelphia, PA
Surgical Management of Primary and Metastatic GIST
and Indications for Adjuvant and Neoadjuvant
Therapy for Primary GIST
Chandrajit P. Raut, Boston, MA
Panel and Audience Discussion
8:30 AM – 10:00 AM SSAT PUBLIC POLICY 243
COMMITTEE/AGA PRACTICE
MANAGEMENT AND ECONOMICS
COMMITTEE JOINT PANEL
HEALTH CARE REFORM AND GASTROINTESTINAL
DISEASES
Moderator: Jonathan R. Hiatt, Los Angeles, CA
Sp543
Sp544
Sp545
Participants will be able to:
• Describe the potential impact of health care reform on
academic health centers; list quality measures used to
assess GI practices, and how these might be used in
health care reform; and describe how health care reform
may lead to integration of digestive disease practice.
Impact of Reform on Academic Health Centers
Michael J. Zinner, Boston, MA
Quality Measures and the Effect on Health Care Reform
Clifford Y. Ko, Los Angeles, CA
What Does a Digestive Disease Practice Look Like in a
Reformed Health Care Model?
Joel Brill, Phoenix, AZ
Panel and Audience Discussion
9:30 AM – 11:00 AM SSAT/AHPBA 244-245
JOINT SYMPOSIUM
TODAY’S APPROACHES TO COLORECTAL
CANCER (CRC) LIVER METASTASES
Moderator: Scott Helton, New Haven, CT
Sp553
Sp554
Sp555
Sp556
Sp557
Participants will be able to:
• Better understand the natural history of colorectal cancer
metastatic to the liver and the tumor biological, staging
and treatment factors that predict long term survival;
understand the pros and cons and rational for neoadjuvant
and adjuvant treatment approaches with
chemotherapy for resectable metastatic colorectal cancers
of the liver; appreciate strategies for individually tailoring
therapy to improve safe extended liver resection for
CRC mets; and better understand nonresectional liver
directed therapies and their impact on outcome for
metastatic colorectal cancer.
Introduction
Scott Helton, New Haven, CT
Prognostic Markers and Staging Systems for Patients
with CRC Metastases
Michael D’Angelica, New York, NY
The Role of Perioperative Chemotherapy in Resectable
CRC Metastases: What Does the Evidence Support?
Timothy M. Pawlik, Baltimore, MD
Optimal and Individually Tailored Resection of CRC
Metastases
Eddie K. Abdalla, Houston, TX
What, How, and When to Offer Non-Resection
Therapy for CRC Metastases
N. Joseph Espat, Providence, RI
Panel and Audience Discussion
DAILY
SCHEDULE
72
73